Mandalay Resources Corporation Announces Production and Sales Results for the First Quarter of 2023

TORONTO, April 18, 2023 /CNW/ – Mandalay Resources Corporation (“Mandalay” or the “Company”) (TSX: MND) (OTCQB: MNDJF) announced…

Primo Water Releases 2021 Supplement to Inaugural 2020 Environmental, Social and Governance Report

Report provides 2021 highlights and progress against stated targets TAMPA, Fla, April 17, 2023 April 17, 2023 – Primo…

ASCENDANT PROVIDES AN UPDATE FOR ITS LAGOA SALGADA POLYMETALLIC PROJECT IN PORTUGAL

TSX: ASND www.ascendantresources.com  Feasibility study expected in May Final Metallurgical Results Expected Shortly Appoints SD Capital…

RBC Global Asset Management Inc. announces RBC ETF cash distributions for April 2023

TORONTO, April 14, 2023 /CNW/ – RBC Global Asset Management Inc. (“RBC GAM Inc.”) today announced April 2023 cash distributions for…

Crystal Lagoons Expands Middle East Success with Saudi Arabia Master Agreement Partnership with A’amal Group.

MIAMI, April 13, 2023 /CNW/ — Crystal Lagoons enters the largest country in the Middle East, Saudi Arabia, with a new mega…

TUMI AND McLAREN COLLABORATE TO CELEBRATE SIX DECADES OF McLAREN WITH THE LAUNCH OF THE 60TH ANNIVERSARY COLLECTION ALONGSIDE LANDO NORRIS

Each piece in the limited-edition collection nods to the history of the renowned elite motorsports and…

Simons unveils its exclusive collection Édito

Passionately committed to high-end fashion QUEBEC CITY, April 12, 2023 /CNW/ – Building on the success of its first Édito…

Ford’s Oakville, Ontario, Manufacturing Site Prepares to Build Next-Gen EVs; C$1.8 Billion Transformation Begins 2024

Ford is investing C$1.8 billion to transform Oakville (Ont.) Assembly Complex into a Canadian hub of electric vehicle manufacturing that…

Omy Laboratoires secures $ 11 million financing round to expand into the U.S. market

Fondaction, BDC Capital and Accelia Capital join forces with Crédit Mutuel Capital to support Omy Laboratoires’ innovative…

Vertex Announces Health Canada Market Authorization for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 1 to <2 Years

–  With this approval, approximately 30 children with two copies of the F508del mutation are eligible…